Concept:
This question asks to identify the odd one out regarding the prognostic factors in Rheumatoid Arthritis (RA). Poor prognostic factors imply a higher likelihood of rapidly progressive, erosive disease with severe functional decline.
Explanation:
• Established poor prognostic factors in RA that predict a more aggressive disease course include:
1. High titers of Rheumatoid Factor (RF) and Anti-Cyclic Citrullinated Peptide (anti-CCP) antibodies.
2. Early presence of joint erosions on radiographs.
3. High acute phase reactants (persistently elevated ESR or CRP).
4. Presence of extra-articular manifestations (e.g., rheumatoid nodules, vasculitis).
5. High degree of functional disability at baseline.
• Option (A) is a poor prognostic factor, indicating aggressive bone destruction is already underway.
• Option (B) and Option (C) are poor prognostic factors; seropositive patients tend to have more severe, erosive disease and are at higher risk for extra-articular manifestations compared to seronegative patients.
• Option (D), Early methotrexate usage, is the cornerstone of modern RA management. Initiating a Disease-Modifying Antirheumatic Drug (DMARD) early in the disease course (within the "window of opportunity") suppresses inflammation, halts radiographic progression, and drastically improves the prognosis. Therefore, it is a good prognostic indicator, making it the exception among the choices.
Final answer:
While the question text lacks the word "NOT", early methotrexate usage is the only factor listed that prevents disease progression, contrasting with the other three universally accepted poor prognostic markers.